genetically engineered mycobacteria (Bacilligen)

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug Namegenetically engineered mycobacteria (Bacilligen)
Drug Alias NamerMB-506rMB-503
ClassificationCell and gene therapy > Cell therapy
Mechanisms of ActionCell replacements
TargetsNot applicable
Therapy Area/IndicationsUrinary Bladder Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesBacilligen Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBacilligen Inc
Active IndicationsN/A
Inactive IndicationsUrinary Bladder Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A